A large multicenter cohort study from Australia examined patients with advanced or refractory cancers treated with genomically matched therapies. Patients had better overall survival only when the treatment had support from prospective studies. Genomically aligned cancer therapies are only as good as the supporting evidence. The study showed that without such support, they do not provide a survival advantage. The results highlight the importance of high-quality evidence for the effective use of these therapies.